Videos

General Cancer

Jurgen Wolf, MD, discusses the importance of broad genomic testing to identify alterations in patients with advanced non–small cell lung cancer (NSCLC). By identifying molecular alterations and driver mutations early on, patients can receive matched targeted therapies at a time in the course of disease when the treatments would have the greatest impact.

Mark G. Kris, MD, discusses the importance of delaying relapse in patients with&nbsp;<em>EGFR</em>-positive non&ndash;small cell lung cancer. He shares the significance of the findings from the phase III RELAY trial, where the goal was to delay the time to relapse by adding ramucirumab to erlotinib.

Phillipe Moreau, MD, discusses the results from the randomized, open-label, multicenter phase III CASSIOPEIA trial. The results of the trial led to&nbsp;a priority review designation from the FDA for the combination of daratumumab plus bortezomib, thalidomide, and dexamethasone for patients with treatment-na&iuml;ve multiple myeloma who are candidates for autologous stem cell transplant.

<em>FLT3</em> mutation analysis in laboratories has brought on reimbursement barriers in clinical oncology. Jordan Clark, chief commercial officer, Diaceutics, a diagnostic development and commercialization company, spoke to <em>Targeted Oncology</em> about the cause of reimbursement issues and how the problem affects all parties involved.

Alexander D. Guminski, MD, PhD, discusses the 12-month follow-up data from a phase II study investigating the role of cemiplimab as a treatment for patients with metastatic cutaneous squamous cell carcinoma.

Hussain Borghaei, DO, MS, discusses the significance of the overall survival data update from the KEYNOTE-001 trial. This trial investigated the PD-1 inhibitor pembrolizumab as a treatment for patients with advanced non&ndash;small cell lung cancer.

Lori A. Leslie, MD, discusses the rationale for investigating the PI3K-delta inhibitor umbralisib in patients with relapsed or refractory marginal zone lymphoma in a multi-center, open-label phase II study. On trial, only patients with MZL were enrolled who had received at least 1 prior line of therapy. These patients received single-agent umbralisib once daily until progression or unacceptable toxicity.

Nikhil I. Khushalani, MD, discusses the rationale for combining nivolumab with bempegaldesleukin for the treatment of patients with newly diagnosed, unresectable or metastatic melanoma in a randomized, open-label phase III trial.

Skin Cancer

Debu Tripathy, MD, of the Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, was an investigator in the phase III MONALEESA-7 trial. The purpose of the study was to examine how endocrine therapy, in combination with a cyclin-dependent kinase inhibitor, affects progression-free survival and overall survival in premenopausal patients with HR-positive, HER2-negative advanced breast cancer.

Addressing the need for treatments that are more effective and less toxic for patients with relapsed or refractory chronic lymphocytic leukemia, Paolo Ghia, MD, of the Universita Vita-Salute San Raffaele, and other researchers conducted a phase III randomized, multicentric ASCEND study, testing acalabrutinib monotherapy in comparison with physician&rsquo;s choice of standard regimens in patients R/R CLL.

Ghanshyam Yadav, MD, a first-year resident in Obstetrics Gynecology &amp; Reproductive Services, Baylor College of Medicine, talks through the results of a preclinical trial that found synergy in the combination of the PARP inhibitor olaparib and the pan-HER tyrosine kinase inhibitor neratinib for uterine serous cancers that overexpress HER2.